Rosetta Genomics, Ltd. and NYU School of Medicine announced that they have expanded their collaboration to include congenital heart disease (CHD). Applying Rosetta Genomics microRNA extraction protocols from various body fluids and NYU School of Medicine's vast experience in this field, this collaboration will screen for specific microRNA biomarkers and signatures that may be used to diagnose and target congenital heart disease in newborns.
About 40,000 infants (1 out of every 125) are born with CHD each year in the United States. The defect may be minor and the baby appears healthy for many years after birth, or severe enough that the baby's life is in immediate danger.
"We have recently put in place a robust diagnostic development engine that includes hundreds of microRNA biomarkers and proprietary technologies," noted Amir Avniel, CEO and President of Rosetta Genomics.
"This engine is what allows us to rapidly expand our pipeline. As a cutting edge research institution, NYU School of Medicine is a close collaborator of Rosetta Genomics in the microRNA field, and I am confident this collaboration will enhance our understanding of the link between microRNAs and various heart conditions," Avniel continued.
"It is now clear that microRNAs play a key role in controlling diverse aspects of cardiac development and response to disease," noted Dr. David B. Meyer, Director of Pediatric and Congenital Cardiothoracic Surgery, at NYU School of Medicine.
"Rosetta Genomics' extensive knowledge and proprietary technologies in the microRNA field, coupled with our experience in CHD, is an excellent starting point for this collaboration," said Meyer.